PT - JOURNAL ARTICLE AU - Actkins, Ky’Era V. AU - Jean-Pierre, Genevieve AU - Aldrich, Melinda C. AU - Velez Edwards, Digna R. AU - Davis, Lea K. TI - Sex Modifies the Effect of Genetic Risk Scores for Polycystic Ovary Syndrome on Metabolic Phenotypes AID - 10.1101/2021.10.23.21265391 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.23.21265391 4099 - http://medrxiv.org/content/early/2021/10/26/2021.10.23.21265391.short 4100 - http://medrxiv.org/content/early/2021/10/26/2021.10.23.21265391.full AB - Females with polycystic ovary syndrome (PCOS), the most common endocrine disorder in women, have an increased risk of developing metabolic disorders such as insulin resistance, obesity, and type 2 diabetes (T2D). Furthermore, while only diagnosable in females, males with a family history of PCOS can also exhibit a poor cardiometabolic profile. Therefore, we aimed to elucidate the role of sex in the relationship between PCOS and its comorbidities by conducting bidirectional genetic risk score analyses in both sexes. We conducted a phenome-wide association study (PheWAS) using PCOS polygenic risk scores (PCOSPRS) to understand the pleiotropic effects of PCOS genetic liability across 1,380 medical conditions in females and males recorded in the Vanderbilt University Medical Center electronic health record (EHR) database. After adjusting for age and genetic ancestry, we found that European descent males with higher PCOSPRS were significantly more likely to develop cardiovascular diseases than females at the same level of genetic risk, while females had a higher odds of developing T2D. Based on observed significant associations, we tested the relationship between PRS for comorbid conditions (e.g., T2D, body mass index, hypertension, etc.) and found that only PRS generated for BMI and T2D were associated with a PCOS diagnosis. We then further decomposed the T2DPRS association with PCOS by adjusting the model for measured BMI and BMIresidual (enriched for the environmental contribution to BMI). Results demonstrated that genetically regulated BMI primarily accounted for the relationship between T2DPRS and PCOS. This was further supported in a mediation analysis, which only revealed clinical BMI measurements, but not BMIresidual, as a strong mediator for both sexes. Overall, our findings show that the genetic architecture of PCOS has distinct metabolic sex differences, but these associations are only apparent when PCOSPRS is explicitly modeled. It is possible that these pathways are less explained by the direct genetic risk of metabolic traits than they are by the risk factors shared between them, which can be influenced by biological variables such as sex.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKVA is funded by F31HD103397. LKD is funded by U54MD010722. MCA is funded by a grant from NIH/NCI (U01CA253560). Datasets were obtained using the Vanderbilt University Advanced Computing Center for Research and Education. This resource is funded by institutional, private, and federal grants, which include NIH funded Shared Instrumentation Grant S10OD017985 and S10RR025141 and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Vanderbilt University Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll GWAS summary statistics used in this study are publicly available and can be obtained from the following consortium groups and websites: International PCOS Consortium (https://doi.org/10.17863/CAM.27720), UK Biobank (http://www.nealelab.is/uk-biobank), HERMES (http://www.broadcvdi.org/), and CARDIoGRAMplusC4D (http://www.cardiogramplusc4d.org/). The summary statistics used from the Million Veteran Project can be accessed through dbGaP under accession number phs001672.v6.p1. The electronic health record data that support the findings of this study are available from Vanderbilt University Medical Center, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of Vanderbilt University Medical Center.